Generic Name: degarelix

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Hormone Therapy Medications

Company: Ferring

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Firmagon is a GnRH receptor blocker approved for advanced prostate cancer.

General Info

Testosterone and other male hormones (androgens) stimulate prostate cancer growth. Gonadotropin-releasing hormone (GnRH) antagonists, also known as luteinizing hormone-releasing hormone (LHRH) antagonists, block signals in the brain that direct the testicles to produce testosterone. It lowers testosterone levels faster than GnRH agonist drugs like Zoladex (goserelin).


Dosing Info:

Firmagon is given as a monthly subcutaenous injection.

Side Effects

Common side effects include injection site reactions, hot flashes, weight gain and liver enzyme elevations. Drugs that lower testosterone may lead to reduced sexual desire, erectile dysfunction and shrinkage of the testicles.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 19, 2018